Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Joan M. Gilmore
Observed name:
Joan Gilmore
Institution:
University of Pennsylvania
Observed institutions:
University of Iowa,
Children's Hospital of Philadelphia,
Washington University in St. Louis,
University of Pennsylvania Health System,
Abramson Cancer Center,
University of Cincinnati,
University of Pennsylvania
show all 7
ORCID:
0000-0001-8975-6602
Observed ORCID:
0000-0001-8975-6602
OpenAlex ID:
A5075558634
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
2022
·
Vivek Narayan
, Julie S. Barber-Rotenberg
, et al.
·
Nature Medicine
·
534
PDF
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
2019
·
Noelle V. Frey
, Pamela A. Shaw
, et al.
·
Journal of Clinical Oncology
·
271
Transcriptional Genomics Associates FOX Transcription Factors With Human Heart Failure
2006
·
Sridhar Hannenhalli
, Mary E. Putt
, et al.
·
Circulation
·
262
PDF
Detection of Cardiac Allograft Rejection and Response to Immunosuppressive Therapy With Peripheral Blood Gene Expression
2004
·
Phillip A. Horwitz
, Emily J. Tsai
, et al.
·
Circulation
·
157
Common Variants in HSPB7 and FRMD4B Associated With Advanced Heart Failure
2010
·
Thomas P. Cappola
, Mingyao Li
, et al.
·
Circulation Cardiovascular Genetics
·
135
PDF
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
2023
·
Payal D. Shah
, Alexander C. Huang
, et al.
·
Cancer Research Communications
·
104
Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL
2014
·
David L. Porter
, Noelle V. Frey
, et al.
·
Blood
·
63
Lack of Association Between an Interleukin 1 Beta (IL‐1β) Gene Variation and Refractory Temporal Lobe Epilepsy
2001
·
Russell J. Buono
, Thomas N. Ferraro
, et al.
·
Epilepsia
·
53
PDF
Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.
2016
·
David L. Porter
, Noelle V. Frey
, et al.
·
Journal of Clinical Oncology
·
34
Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL
2013
·
David L. Porter
, Michael Kalos
, et al.
·
Blood
·
29
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
2019
·
Vivek Narayan
, Whitney Gladney
, et al.
·
Journal of Clinical Oncology
·
28
Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL
2012
·
David L Porter
, Stephan A. Grupp
, et al.
·
Blood
·
25
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
2020
·
Vivek Narayan
, Whitney Gladney
, et al.
·
Journal of Clinical Oncology
·
21
Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL
2013
·
David L. Porter
, Michael Kalos
, et al.
·
Blood
·
20
A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
2021
·
Vivek Narayan
, Julie Barber-Rotenberg
, et al.
·
Journal of Clinical Oncology
·
17
Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
2019
·
Elise A. Chong
, James N. Gerson
, et al.
·
Blood
·
10
Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells
2020
·
Natalie F. Uy
, Edward Pequignot
, et al.
·
Blood
·
9
A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).
2013
·
David L. Porter
, Noelle V. Frey
, et al.
·
Journal of Clinical Oncology
·
6
Abstract 4874: Large-Scale Candidate Gene Association with Human Heart Failure
2008
·
Thomas Cappola
, Mingyao Li
, et al.
·
Circulation
·
2
TABLE 3 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
2023
·
Payal D. Shah
, Alexander C. Huang
, et al.
FIGURE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
2023
·
Payal D. Shah
, Alexander C. Huang
, et al.
TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
2023
·
Payal D. Shah
, Alexander C. Huang
, et al.
TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
2023
·
Payal D. Shah
, Alexander C. Huang
, et al.
Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
2023
·
Payal D. Shah
, Alexander C. Huang
, et al.
Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
2023
·
Payal D. Shah
, Alexander C. Huang
, et al.
Show more works
View as search
Works count:
45
Citation count:
1,779
H-index:
15
I10-index:
16
Year
Topic
Type
